PENTOSAN POLYSULPHATE INFLUENCEON THE COURSE OF CHRONICKIDNEYDISEASE ST'. II - IV
Abstract
The aim is to determine the effect of the drug pentosan polysulphate at the rate of disease progression in patients with CKD II - IVst., to confirmation of lipid - lowering action and setting of the drug on indicators of chronic inflammation.
Materials and methods. Tests conducted in one center for 12 weeks. The study included 60patients with CKD II - IV st. Patients were divided into 2 groups: group 1 (basic) - 30patients in addition to standard therapy receiving study medication, pentosan polysulphate, group 2 - 30 patients received only standard therapy. The drug pentosan polysulphate was administered for 8 - weeks: 100 mg. a day intramuscularly or intravenously for 3 weeks, followed by oral administration of 50 mg two times a day. The survey studied the dynamics ofdaily proteinuria, GFR, lipids, indicators of tumor necrosis factor, IL - 18 and vascular endothelial growth factor (VEGF) before and after treatment (12 week observation).
Results. It was found a significant decrease in total cholesterol and atherogenic ratio after 3 months of treatment in the study group, hypolipidemic effect is more significant than in the comparison group. The group used pentosan polysulphate proteinuria reduction was more pronounced, and was 65% against 38% in the comparison group. Pentosan polysulphate in the treatment ofCKDpatients in stages II - IV contributes to significant decrease in inflammatory cytokines (IL - 18 and TNF - a) in contrast to the comparison group.
Conclusions. The use of pentosan polysulphate in the treatment of patients with CKD stages II - IV had positive effect on lipid metabolism. Purpose pentosan polysulphate patients with CKD stages II - IV contributes to a significant reduction of the daily proteinuria and eGFR improvement, reduces levels of inflammatory cytokines: IL - 18 and TNF - a.
Downloads
References
UN General Assembly. Political declaration of the high - level meeting of the general assembly on the prevention and control of non - communicable diseases. A/66/L.1. http://www.un.org/ga/search/view_doc.asp?symbol= A/6 6/L. 1; http: //www.un. org/ ga/search/ view_doc.asp?symbol=A/66/L.1; Sept 16, 2011. ((accessed June 30, 2012).)
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System. Atlanta. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2011. http://www. cdc.gov/ckd. Accessed August 5, 2013.
Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // Kidney inter. - 2013. - Vol. 3, Suppl. - P. 1 - 150.
National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007: 49 (Suppl 2): S l - 180.
National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39 [Suppl 1]: S1–S266
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition / Y. Liu, J. Coresh, J. A. Eustace [et al.] // JAMA. – 2004. - Vol. 291. - Р. 451 - 459.
Drake T. B. Atherosclerosis in CKD: differences from the general population / T. B. Drake, Z. A. Massy // Nat. Rev. Nephrol. - 2010. - Vol. 6. - P. 723 - 735
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta - analysis / W. Hou, J Lv, V. Perkovic [et al.] // Eur. Heart. J. - 2013. - Vol. 34. - P. 18.
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. // Kidney inter. - 2013. - Vol.3, Suppl. - P. 259 - 305.
Atorvastatin and low - density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis / W. Marz, B. Genser, C. Drechsler [et al.] // Clin. J. Am. Soc. Nephrol. - 2011. - Vol. 6. - P. 1316 - 1325.
Kleemann R, Zadelddr S., Kooistra T. Cytokines and atherosclerosis: comprehensive review of studies in mice. Cardiovasc Res. - 2008. - №79. - Р. 360 - 376.
Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus [Text] / B. Laczy [et al.] // Acta Diabetol. - 2009. - Vol. 46, № 2. - P. 105 - 111.
Ханюкова И.Я. Влияние пентосана полисульфата на показатели гемостаза и липидного обмена у больных ИБС / И.Я. Ханюкова, А.В. Танцура // Укр. терапевт. журн. – 2008. – № 1. – С. 80 - 83.
Кравчун Н.А., Чернявская И.В. Комплексная терапия микрососудистых осложнений у пациентов с сахарным диабетом 2 - го типа с применением антитромботических препаратов / Н.А. Кравчун, И.В. Чернявская // Международный эндокринологический журнал. – 2012. – № 5(45). – С. 31 - 35.
Никульников П.И., Ратушнюк А.А., Гуч А.А. Профилактика тромботических осложнений реконструктивных операций, выполненных по поводу окклюзии магистральных артерий бедренно - подколенного сегмента / П.И. Никульников, А.А. Ратушнюк, А.А. Гуч // Клінічна хірургія. – 2008. – № 7. – С. 24 - 27.
